-
公开(公告)号：US12116638B2
公开(公告)日：2024-10-15
申请号：US17673718
申请日：2022-02-16
Applicant: Foundation Medicine, Inc.
Inventor： Maureen T. Cronin , Garrett Michael Frampton , Doron Lipson , Vincent A. Miller , Gary Palmer , Jeffrey S. Ross , Philip James Stephens , Roman Yelensky
IPC: C12Q1/6886 , A61K31/416 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/436 , A61K31/437 , A61K31/439 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K31/565 , A61K31/567 , A61K31/675 , A61K45/06 , C07K14/72 , C07K16/28
CPC classification number: C12Q1/6886 , A61K31/416 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/436 , A61K31/437 , A61K31/439 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K31/565 , A61K31/567 , A61K31/675 , A61K45/06 , C07K14/72 , C07K16/2869 , C07K2317/34 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
Abstract: Novel mutant ESR1 molecules and uses are disclosed.
-
公开(公告)号：US11771698B2
公开(公告)日：2023-10-03
申请号：US17204830
申请日：2021-03-17
Applicant: Foundation Medicine, Inc.
Inventor： Siraj Mahamed Ali , Matthew J. Hawryluk , Jie He , Doron Lipson , Vincent A. Miller , Jeffrey S. Ross , Philip James Stephens
IPC: A61K31/517 , A61K31/498 , A61K31/19 , A61K31/5025 , C12N9/12 , A61K31/4412 , A61K45/06 , A61K31/47 , A61K31/435 , A61K31/506 , A61K31/519 , A61K31/4439 , A61K31/53 , A61K31/404 , A61K31/5383 , A61K31/496 , C12Q1/6886 , A61K31/553 , C07K14/705 , C07K14/71 , C07K16/40 , C12N15/113 , C12Q1/6883 , G01N33/573
CPC classification number: A61K31/5025 , A61K31/404 , A61K31/435 , A61K31/4412 , A61K31/4439 , A61K31/47 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5383 , A61K31/553 , A61K45/06 , C07K14/705 , C07K14/71 , C07K16/40 , C12N9/12 , C12N15/1137 , C12Q1/6883 , C12Q1/6886 , C12Y207/10001 , G01N33/573 , C07K2319/00 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12Q2600/156 , C12Q2600/158 , G01N2333/912 , G01N2500/04
Abstract: Methods and compositions for treating cholangiocarcinoma.
-
公开(公告)号：US20180320238A1
公开(公告)日：2018-11-08
申请号：US15877035
申请日：2018-01-22
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Maureen T. Cronin , Garrett Michael Frampton , Doron Lipson , Vincent A. Miller , Gary Palmer , Jeffrey S. Ross , Philip James Stephens , Roman Yelensky
IPC: C12Q1/6886 , A61K31/675 , A61K31/565 , A61K31/436 , A61K31/4439 , C07K16/28 , A61K31/416 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/472 , A61K31/536 , A61K31/5415 , C07K14/72 , A61K31/567 , A61K45/06 , A61K31/439 , A61K31/4196
CPC classification number: C12Q1/6886 , A61K31/416 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/436 , A61K31/437 , A61K31/439 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K31/565 , A61K31/567 , A61K31/675 , A61K45/06 , C07K14/72 , C07K16/2869 , C07K2317/34 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156
Abstract: Novel mutant ESR1 molecules and uses are disclosed.
-
公开(公告)号：US10093983B2
公开(公告)日：2018-10-09
申请号：US14753397
申请日：2015-06-29
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Maureen T. Cronin , Garrett Michael Frampton , Doron Lipson , Vincent A. Miller , Gary Palmer , Jeffrey S. Ross , Philip James Stephens , Roman Yelensky
IPC: G01N33/53 , C12Q1/6886 , A61K31/4196 , A61K31/565 , A61K31/675 , A61K31/439 , A61K31/567 , A61K31/416 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/472 , A61K31/536 , A61K31/5415 , A61K45/06 , C07K14/72 , C07K16/28 , A61K31/436
Abstract: Novel mutant ESR1 molecules and uses are disclosed.
-
公开(公告)号：US20170014413A1
公开(公告)日：2017-01-19
申请号：US15045716
申请日：2016-02-17
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Sean R. Downing , Matthew J. Hawryluk , Doron Lipson , Alexander N. Parker , Philip James Stephens
IPC: A61K31/517 , A61K31/47 , A61K31/513 , A61K31/4412 , A61K31/404
CPC classification number: A61K31/517 , A61K31/404 , A61K31/4412 , A61K31/444 , A61K31/47 , A61K31/513 , C07K14/82 , C07K2319/00 , C12N9/14 , C12N15/1135 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158
Abstract: Novel RET fusion molecules and uses are disclosed. In one embodiment, a KIF5B-RET fusion includes an in-frame fusion of an exon of KIF5B (e.g., one or more exons encoding a kinesin motor domain or a fragment thereof) and an exon of RET (e.g., one or more exons encoding a RET tyrosine kinase domain or a fragment thereof). For example, the KIF5B-RET fusion can include an in-frame fusion of at least exon 15 of KIF5B or a fragment thereof (e.g., exons 1-15 of KIF5B or a fragment thereof) with at least exon 12 of RET or a fragment thereof (e.g., exons 12-20 of RET or a fragment thereof).
Abstract translation: 公开了新型RET融合分子和用途。 在一个实施方案中，KIF5B-RET融合包括KIF5B的外显子（例如，编码驱动蛋白运动区或其片段的一个或多个外显子）和RET的外显子（例如，一个或多个外显子编码 RET酪氨酸激酶结构域或其片段）。 例如，KIF5B-RET融合可以包括至少外显子15的KIF5B或其片段（例如，KIF5B的外显子1-15或其片段）与至少外显子12的RET或片段的片段内融合 （例如，RET的外显子12-20或其片段）。
-
Patent Agency Ranking
公开(公告)号：US12274699B2
公开(公告)日：2025-04-15
申请号：US18346029
申请日：2023-06-30
Applicant: Foundation Medicine, Inc.
Inventor： Siraj Mahamed Ali , Matthew J. Hawryluk , Jie He , Doron Lipson , Vincent A. Miller , Jeffrey S. Ross , Philip James Stephens
IPC: A61K31/517 , A61K31/19 , A61K31/404 , A61K31/435 , A61K31/4412 , A61K31/4439 , A61K31/47 , A61K31/496 , A61K31/498 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/53 , A61K31/5383 , A61K31/553 , A61K45/06 , C07K14/705 , C07K14/71 , C07K16/40 , C12N9/12 , C12N15/113 , C12Q1/6883 , C12Q1/6886 , G01N33/573
Abstract: Methods and compositions for treating cholangiocarcinoma.
-
公开(公告)号：US12180540B2
公开(公告)日：2024-12-31
申请号：US17812415
申请日：2022-07-13
Applicant: Foundation Medicine, Inc.
Inventor： Doron Lipson , Geoffrey Alan Otto , Alexander Nevin Parker , Philip James Stephens , Sean R. Downing , Mirna Jarosz , Mikhail G. Shapiro , Roman Yelensky
IPC: C12Q1/6827 , C12Q1/6874 , C12Q1/6886 , G16B20/00 , G16B20/10 , G16B20/20 , G16B30/00 , G16B30/10
Abstract: A method of analyzing a tumor sample comprising: (a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.
-
公开(公告)号：US11959141B2
公开(公告)日：2024-04-16
申请号：US15529237
申请日：2015-12-04
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Geoffrey Alan Otto , Michelle Nahas , Doron Lipson
IPC: C12Q1/68 , C12N15/10 , C12Q1/6806 , C12Q1/6886 , G16B25/00 , G16B25/10 , G16B30/00 , G16B30/10 , G16B45/00
CPC classification number: C12Q1/6886 , C12N15/1065 , C12Q1/6806 , G16B25/00 , G16B25/10 , G16B30/00 , G16B30/10 , G16B45/00 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , C12Q1/6806 , C12Q2535/122 , C12Q2537/159 , C12Q2563/131
Abstract: Methods of evaluating or providing a clonal profile of a subject interval, e.g., a subgenomic interval, or an expressed subgenomic interval (or of a cell containing the same), in a subject, are disclosed.
-
公开(公告)号：US11674962B2
公开(公告)日：2023-06-13
申请号：US16041363
申请日：2018-07-20
Applicant: Genentech, Inc. , Foundation Medicine, Inc.
Inventor： Craig Anthony Cummings , Yan Li , Sarah Margaret Shagan , Erica Beth Schleifman , David Shames , David Fabrizio , Daniel Lieber , Geoffrey Alan Otto , Mark Kennedy , Travis Clark , Doron Lipson , Jie He , Shan Zhong
IPC: C12Q1/68 , C12Q1/6883 , G01N33/574 , C07K16/28 , G16H50/50 , G16H50/30 , G16H50/70 , G16H50/20 , A61P35/00 , G06F16/28 , C07K14/735 , A61K39/00
CPC classification number: G01N33/574 , A61P35/00 , C07K14/70535 , C07K16/2827 , C07K16/2896 , C12Q1/68 , C12Q1/6883 , G01N33/57492 , G06F16/285 , G16H50/20 , G16H50/30 , G16H50/50 , G16H50/70 , A61K2039/505 , A61K2039/55 , C07K2317/24 , C12Q2600/156 , G01N2333/70532 , G01N2800/52
Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
-
公开(公告)号：US20180280391A1
公开(公告)日：2018-10-04
申请号：US15839560
申请日：2017-12-12
Applicant: FOUNDATION MEDICINE, INC.
Inventor： Sean R. Downing , Matthew J. Hawryluk , Doron Lipson , Alexander N. Parker , Philip James Stephens
IPC: A61K31/517 , C12N15/113 , A61K31/513 , C07K14/82 , A61K31/4412 , A61K31/404 , A61K31/47 , C12Q1/6886 , C12N9/14 , A61K31/444
Abstract: Novel RET fusion molecules and uses are disclosed.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.029 seconds)
